ライフサイエンスコーパス: chronic hepatitis C

1 nse to peginterferon alpha/ribavirin (PR) in chronic hepatitis C.

2 hly effective for treatment of patients with chronic hepatitis C.

3 f patients with alcohol-related cirrhosis or chronic hepatitis C.

4 n the response to IFN-alpha-based therapy of chronic hepatitis C.

5 g pegIFN-alpha injection in 18 patients with chronic hepatitis C.

6 FN)-induced viral clearance in patients with chronic hepatitis C.

7 ts for prevention of hepatocarcinogenesis in chronic hepatitis C.

8 antiviral responses in patients affected by chronic hepatitis C.

9 on sustained viral response in patients with chronic hepatitis C.

10 nterferon/ribavirin therapy in patients with chronic hepatitis C.

11 hat is likely beneficial in the treatment of chronic hepatitis C.

12 st medical history was notable, however, for chronic hepatitis C.

13 itis B infection and 23 patients (11.2%) had chronic hepatitis C.

14 g its therapeutic potential in patients with chronic hepatitis C.

15 and fibrosis in two cohorts of patients with chronic hepatitis C.

16 USION: FD is more prevalent in patients with chronic hepatitis C.

17 as highlighted by the case of the therapy of chronic hepatitis C.

18 ated with reduced hepcidin expression, e.g., chronic hepatitis C, alcoholic liver disease, or heredit

19 This study included 252 patients with chronic hepatitis C and 150 healthy volunteers.

20 Hepcidin production is often insufficient in chronic hepatitis C and alcoholic liver disease, leading

21 Patients with chronic hepatitis C and insulin resistance are less like

22 indices of glycemic control in patients with chronic hepatitis C and insulin resistance, but did not

23 onsistent with these findings, patients with chronic hepatitis C and nonalcoholic steatohepatitis sig

24 can capture nonlinear disease progression in chronic hepatitis C and thus outperform baseline models.

25 ng cholangitis, alcoholic liver disease, and chronic hepatitis C), and human cholangiocytes expressed

26 three PIs have been approved for therapy of chronic hepatitis C, and several others are in developme

27 udy, we elucidate the potential link between chronic hepatitis C-associated inflammation and alterati

28 ially studied and validated in patients with chronic hepatitis C but are now used increasingly for pa

29 Chronic hepatitis C can result in progressive liver dise

30 known whether chronic hepatitis B (CH-B) or chronic hepatitis C (CH-C) carries a greater risk of liv

31 ] allele is more represented in HCC cases in chronic hepatitis C (CHC) and alcoholic liver disease (A

32 131 HCC patients, 76 cirrhosis patients, 52 chronic hepatitis C (CHC) and B (CHB) patients, and 53 h

33 Most of these markers have been developed in chronic hepatitis C (CHC) and nonalcoholic fatty liver d

34 d genes (ISGs) in the liver of patients with chronic hepatitis C (CHC) are not known.

35 FLD and liver damage progression in NASH and chronic hepatitis C (CHC) by still undefined mechanisms,

36 Patients with chronic hepatitis C (CHC) exhibit reduced work productiv

37 mproving prediction of treatment outcomes in chronic hepatitis C (CHC) genotype 4 (G4) is necessary t

38 Approximately 50% of patients with chronic hepatitis C (CHC) have a sustained virologic res

39 Approximately 50% of patients with chronic hepatitis C (CHC) have ongoing expression of int

40 In resource-rich countries, chronic hepatitis C (CHC) infection is associated with a

41 Liver mortality among individuals with chronic hepatitis C (CHC) infection is common, but the r

42 the standard of care (SOC) for patients with chronic hepatitis C (CHC) infection.

43 he severity of liver disease associated with chronic hepatitis C (CHC) on healthcare costs has not be

44 rowing evidence that vitamin D is related to chronic hepatitis C (CHC) pathogenicity.

45 (TVR)-based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated accordi

46 compensation, and their time relationship in chronic hepatitis C (CHC) patients remains unclear.

47 se (ALT) elevation and associated factors in chronic hepatitis C (CHC) patients who achieved undetect

48 supplementation on serum fibrotic markers in chronic hepatitis C (CHC) patients.

49 treatment response to interferon therapy in Chronic Hepatitis C (CHC) patients.

50 Treatment guidance for chronic hepatitis C (CHC) released by the American Assoc

51 pe of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication f

52 latelet count < 50,000/muL) in patients with chronic hepatitis C (CHC) undergoing antiviral therapy,

53 about mortality rates (MRs) in patients with chronic hepatitis C (CHC) with cirrhosis is limited.

54 hort of 4,172 patients, including 3,129 with chronic hepatitis C (CHC), 555 with chronic hepatitis B

55 nic course: n = 17), 12 HIV(+) patients with chronic hepatitis C (CHC), 8 HIV monoinfected individual

56 ith confirmed early PBC, 10 with early stage chronic hepatitis C (CHC), and nine with resolving, self

57 In patients with chronic hepatitis C (CHC), cirrhosis is associated with

58 assess the accuracy of SWE in patients with chronic hepatitis C (CHC), in comparison with transient

59 epatitis C virus (HCV) is a leading cause of chronic hepatitis C (CHC), liver cirrhosis, and hepatoce

60 t hepatitis C virus (HCV) infection leads to chronic hepatitis C (CHC), which often progresses to liv

61 actors influence liver damage progression in chronic hepatitis C (CHC).

62 m treatment decisions in adult patients with chronic hepatitis C (CHC).

63 eated noninvasive tests of liver fibrosis in chronic hepatitis C (CHC).

64 B1 and CB2 gene expression, in patients with chronic hepatitis C (CHC).

65 gical and clinical outcomes in patients with chronic hepatitis C (CHC).

66 may contribute to an unfavorable outcome of chronic hepatitis C (CHC).

67 ined by histologic analysis in patients with chronic hepatitis C (CHC).

68 a/ribavirin (PR) in patients with genotype 1 chronic hepatitis C (CHC).

69 y untreated patients with genotype 1 (G(1) ) chronic hepatitis C (CHC).

70 play important roles in the pathogenesis of chronic hepatitis C (CHC).

71 We performed a cross-sectional study of chronic hepatitis C (cHCV) patients using tetramer-assoc

72 Despite effective treatment for chronic hepatitis C, deficiencies in diagnosis and acces

73 allenges include increasing awareness of the chronic hepatitis C epidemic, garnering sufficient publi

74 diovascular risk in patients with genotype 1 chronic hepatitis C (G1 CHC).

75 e inhibitors as part of standard therapy for chronic hepatitis C genotype 1 infection, drug-drug inte

76 m 640 Japanese patients who were treated for chronic hepatitis C genotype 1, 2, or 3 with pegylated i

77 A total of 3070 treatment-naive, chronic hepatitis C genotype 1-infected patients were tr

78 BV alone in previously untreated adults with chronic hepatitis C genotype 1.

79 ntial Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand.

80 Both HBV and chronic hepatitis C guidelines had greatest increases in

81 terferon (PEG-IFN)-alpha in the treatment of chronic hepatitis C has led to an increase in sustained

82 Therapeutic options for treatment of chronic hepatitis C have improved substantially since th

83 ive models of risk of disease progression in chronic hepatitis C have limited accuracy.

84 Trials of therapies for chronic hepatitis C have used detection of hepatitis C v

85 A new standard of care for the treatment of Chronic Hepatitis C (HCV) emerged in 2011 with the appro

86 pproved for response-guided-therapy (RGT) of chronic hepatitis C (HCV) genotype-1-infection in treatm

87 f Ledipasvir/Sofosbuvir for the treatment of chronic hepatitis C (HCV) includes the truncation of the

88 Patients with chronic hepatitis C (HCV) infection have high prevalence

89 Acute and chronic hepatitis C (HCV) infections are prevalent in cu

90 Less is known about its association with chronic hepatitis C (HCV) outcomes.

91 n in retrospective analyses of patients with chronic hepatitis C (HCV).

92 liver damage, especially in individuals with chronic hepatitis C (HCV); however, the impact of nonhea

93 Chronic liver diseases (CLDs), due to chronic hepatitis C; hepatitis B; nonalcoholic fatty liv

94 the management of acute infectious diseases, chronic hepatitis C, human immunodeficiency virus, and a

95 In chronic hepatitis C, IL28B variants associated with poor

96 ession analysis, methadone doses (P = .005), chronic hepatitis C-induced cirrhosis (P = .008), and be

97 ors for prolongation of the QTc interval are chronic hepatitis C-induced cirrhosis, higher methadone

98 the past decade, the standard treatment for chronic hepatitis C infection has been pegylated-interfe

99 Compared with other countries, patients with chronic hepatitis C infection in Japan tend to be older,

100 ould suggest a secondary Mooren ulcer, but a chronic hepatitis C infection was detected.

101 of hepatitis and fibrosis progression during chronic hepatitis C infection, while contrasting results

102 lly effective interferon-free treatments for chronic hepatitis C infection.

103 eks is highly effective for the treatment of chronic hepatitis C infection.

104 ith sickle cell disease are at high risk for chronic hepatitis C infection.

105 diseased livers explanted from patients with chronic hepatitis C infection.

106 nterferon-free regimens for the treatment of chronic hepatitis C infections needs to be evaluated in

107 Chronic hepatitis C is associated with immune infiltrati

108 study suggests that the long-term course of chronic hepatitis C is determined early in infection and

109 The treatment of chronic hepatitis C is rapidly evolving from triple ther

110 erexpression of FBP1 in most HCC tumors with chronic hepatitis C is significantly linked with the dec

111 The study included 1785 patients with chronic hepatitis C, liver biopsy, blood fibrosis tests,

112 Chronic hepatitis C may follow a mild and stable disease

113 ymorphisms at ITPA and treatment efficacy in chronic hepatitis C mediated by reduced relapse risk.

114 ame organ (liver) derived from patients with chronic hepatitis C: On the one side, cirrhotic and tumo

115 mbined cohort of non-cirrhotic patients with chronic hepatitis C or alcoholic liver disease (n = 1121

116 An association between male gender and chronic hepatitis C outcome (P value 0.041) was found.

117 The treatment of chronic hepatitis C patients before they developed cirrh

118 The gold standard therapy for chronic hepatitis C patients is pegylated interferon com

119 This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment e

120 Additionally, 3150 (59.1%) chronic hepatitis C patients were immune or vaccinated a

121 Among 5328 chronic hepatitis C patients, 2998 (56.3%) were immune o

122 infected Huh7 cells and in liver tissue from chronic hepatitis C patients.

123 atosteatosis, a common pathology observed in chronic hepatitis C patients.

124 appears to affect early VKs in patients with chronic hepatitis C receiving interferon-free treatment.

125 various liver diseases; however, its role in chronic hepatitis C remains unclear.

126 n-free, direct-acting antiviral treatment of chronic hepatitis C, subjects who received ribavirin had

127 t has recently been applied to patients with chronic hepatitis C, successfully clearing hepatitis C v

128 evaluate the acute response of patients with chronic hepatitis C to IFN-alpha therapy.

129 notype affects the response of patients with chronic hepatitis C to peginterferon and ribavirin, litt

130 owledge, none of the studies of vitamin D in chronic hepatitis C treatment have included a significan

131 een the 25(OH)D concentration and genotype 1 chronic hepatitis C treatment response in African Americ

132 Chronic hepatitis C viral (HCV) infection has been assoc

133 Emerging therapies for chronic hepatitis C viral (HCV) infection involve inhibi

134 ith hepatocellular carcinoma and concomitant chronic hepatitis C viral infection.

135 ced hepatocellular carcinoma and concomitant chronic hepatitis C viral infection.

136 y activity and fibrosis in 551 patients with chronic hepatitis C virus (HCV) and 203 patients with ch

137 Rates of hospitalization due to chronic hepatitis C virus (HCV) are increasing in Canada

138 Many patients with chronic hepatitis C virus (HCV) are on prolonged proton-

139 ring nonalcoholic steatohepatitis (NASH) and chronic hepatitis C virus (HCV) compared to alcohol live

140 for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infect

141 proved in the United States for treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infecti

142 proved in the United States for treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infecti

143 hase 3 study in previous non-responders with chronic hepatitis C virus (HCV) genotype 1 infection and

144 Interferon-free treatment of chronic hepatitis C virus (HCV) genotype 1 infection may

145 telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, in

146 virin in treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection.

147 ogical response (SVR) rates in patients with chronic hepatitis C virus (HCV) genotype 1 infections, b

148 virin (RBV) in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 without cirrh

149 ective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infe

150 tions are rapidly evolving for patients with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infec

151 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) genotype 2 have high rat

152 eatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infectio

153 ermine the optimal regimen for patients with chronic hepatitis C virus (HCV) genotype 2, 3, 4, or 6 i

154 ed regimens in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 4 infection.

155 ear, the landscape of therapy for genotype 1 chronic hepatitis C virus (HCV) has changed dramatically

156 Chronic hepatitis C virus (HCV) has emerged as a threat

157 nomic burden imposed by the complications of chronic hepatitis C virus (HCV) infection - including ci

158 rect-acting antiviral agents that can cure a chronic hepatitis C virus (HCV) infection after 8-12 wee

159 Treatment of chronic hepatitis C virus (HCV) infection after renal al

160 The prevalence of chronic hepatitis C virus (HCV) infection among incarcer

161 ng evidence indicates an association between chronic hepatitis C virus (HCV) infection and B-cell lym

162 ns are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis.

163 previr regimen for 12 weeks in patients with chronic hepatitis C virus (HCV) infection and stage 4-5

164 ole of MAIT cells in livers of patients with chronic hepatitis C virus (HCV) infection and their fate

165 Patients with cirrhosis resulting from chronic hepatitis C virus (HCV) infection are at risk of

166 trials have demonstrated that patients with chronic hepatitis C virus (HCV) infection associated HCC

167 Chronic hepatitis C virus (HCV) infection can lead to li

168 Chronic hepatitis C virus (HCV) infection causes a subst

169 Chronic hepatitis C virus (HCV) infection causes inducti

170 ons in the peripheral blood of patients with chronic hepatitis C virus (HCV) infection compared to su

171 An unbiased genome-to-genome analysis in chronic hepatitis C virus (HCV) infection confirms the i

172 Whether chronic hepatitis C virus (HCV) infection decreases humo

173 d neurocognitive impairment in patients with chronic hepatitis C virus (HCV) infection even before li

174 eron-alpha (IFNalpha) has been used to treat chronic hepatitis C virus (HCV) infection for over 20 ye

175 Chronic hepatitis C virus (HCV) infection greatly increa

176 Chronic hepatitis C virus (HCV) infection has become a m

177 Chronic hepatitis C virus (HCV) infection has been impli

178 Although chronic hepatitis C virus (HCV) infection has been treat

179 direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstra

180 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infection have high rate

181 Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney tran

182 nd: Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney tran

183 interferon- and ribavirin-free treatment for chronic hepatitis C virus (HCV) infection in patients co

184 Chronic hepatitis C virus (HCV) infection in patients wi

185 to improve access to care and treatment for chronic hepatitis C virus (HCV) infection in resource-li

186 Knowledge of the number of persons with chronic hepatitis C virus (HCV) infection in the United

187 The existing standard of care for chronic hepatitis C virus (HCV) infection includes the u

188 Chronic hepatitis C virus (HCV) infection is a global he

189 BACKGROUND & AIMS: Chronic hepatitis C virus (HCV) infection is a major bur

190 Chronic hepatitis C virus (HCV) infection is a serious d

191 , interferon-alpha (IFN-alpha) treatment for chronic hepatitis C virus (HCV) infection is an ideal mo

192 Chronic hepatitis C virus (HCV) infection is associated

193 Chronic hepatitis C virus (HCV) infection is associated

194 A key question in care of patients with chronic hepatitis C virus (HCV) infection is beginning t

195 Chronic hepatitis C virus (HCV) infection is characteriz

196 Chronic hepatitis C virus (HCV) infection is characteriz

197 Chronic hepatitis C virus (HCV) infection is complicated

198 The efficacy of antiviral treatment for chronic hepatitis C virus (HCV) infection is determined

199 Treatment for chronic hepatitis C virus (HCV) infection is evolving fr

200 Chronic hepatitis C virus (HCV) infection is frequently

201 Prevalence of chronic hepatitis C virus (HCV) infection is high among

202 and ribavirin (IFN-alpha/RBV) treatment for chronic hepatitis C virus (HCV) infection is influenced

203 Chronic hepatitis C virus (HCV) infection is more preval

204 Chronic hepatitis C virus (HCV) infection is one of the

205 Chronic hepatitis C virus (HCV) infection is one of the

206 of liver disease in untreated children with chronic hepatitis C virus (HCV) infection is poorly docu

207 The mechanism of how chronic hepatitis C virus (HCV) infection leads to such

208 e status in liver and blood of patients with chronic hepatitis C virus (HCV) infection long after the

209 th human immunodeficiency virus (HIV) and/or chronic hepatitis C virus (HCV) infection may be prescri

210 Chronic hepatitis C virus (HCV) infection may progress t

211 In Egypt, chronic hepatitis C virus (HCV) infection occurs in arou

212 ere are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients wh

213 The immuno-pathogenic mechanisms of chronic hepatitis C virus (HCV) infection remain to be e

214 Diagnosis of chronic hepatitis C virus (HCV) infection requires both

215 eprevir- and telaprevir-based treatments for chronic hepatitis C virus (HCV) infection use specific r

216 increases treatment efficacy for genotype 1 chronic hepatitis C virus (HCV) infection versus PEG-IFN

217 Patients with chronic hepatitis C virus (HCV) infection who have not h

218 Chronic hepatitis C virus (HCV) infection with advanced

219 Treatment of chronic hepatitis C virus (HCV) infection with direct-ac

220 is a major complication during treatment of chronic hepatitis C virus (HCV) infection with interfero

221 ee, complete regimen for adult patients with chronic hepatitis C virus (HCV) infection without cirrho

222 For the 8810 patients with chronic hepatitis C virus (HCV) infection, 75% were aged

223 ting antivirals (DAAs) effectively eradicate chronic hepatitis C virus (HCV) infection, although HCV

224 Fibrosis is associated with chronic hepatitis C virus (HCV) infection, although the

225 have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more effi

226 inistration to treat persons with genotype 1 chronic hepatitis C virus (HCV) infection, but not those

227 to a high cure rate in treated patients with chronic hepatitis C virus (HCV) infection, but this stil

228 d with clinical and histological features of chronic hepatitis C virus (HCV) infection, including nec

229 nterferon and ribavirin for the treatment of chronic hepatitis C virus (HCV) infection, increase the

230 course of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, we examined t

231 ent standard of care combination therapy for chronic hepatitis C virus (HCV) infection, yet the compo

232 egimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection.

233 and poor physical health among patients with chronic hepatitis C virus (HCV) infection.

234 n associated with liver fibrosis severity in chronic hepatitis C virus (HCV) infection.

235 table ex vivo by conventional methods during chronic hepatitis C virus (HCV) infection.

236 4 protease inhibitor in phase III trials for chronic hepatitis C virus (HCV) infection.

237 HCC) compared to genotype 2 in patients with chronic hepatitis C virus (HCV) infection.

238 (SVR) is the major end point of therapy for chronic hepatitis C virus (HCV) infection.

239 ation therapy is desirable for patients with chronic hepatitis C virus (HCV) infection.

240 feron-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection.

241 feron alfa remains the central treatment for chronic hepatitis C virus (HCV) infection.

242 uction by CD4(+) T cells in individuals with chronic hepatitis C virus (HCV) infection.

243 sted and overexpress inhibitory molecules in chronic hepatitis C virus (HCV) infection.

244 ve focused on their effects in patients with chronic hepatitis C virus (HCV) infection.

245 ) play a central role in the pathogenesis of chronic hepatitis C virus (HCV) infection.

246 Multiple treatments are available for chronic hepatitis C virus (HCV) infection.

247 of liver cirrhosis exists for patients with chronic hepatitis C virus (HCV) infection.

248 or advance in the treatment of patients with chronic hepatitis C virus (HCV) infection.

249 d interferon gamma (IFN-gamma) production in chronic hepatitis C virus (HCV) infection.

250 he most common extrahepatic manifestation of chronic hepatitis C virus (HCV) infection.

251 eficiency virus (HIV)-positive patients with chronic hepatitis C virus (HCV) infection.

252 egimens have been approved for children with chronic hepatitis C virus (HCV) infection.

253 f viral eradication to >90% in patients with chronic hepatitis C virus (HCV) infection.

254 e natural history and treatment responses of chronic hepatitis C virus (HCV) infection; however, dist

255 The ability to classify acute versus chronic hepatitis C virus (HCV) infections at the time o

256 All patients with chronic hepatitis C virus (HCV) infections can and shoul

257 nterferon-free regimens for the treatment of chronic hepatitis C virus (HCV) infections require furth

258 The evolution of treatment for patients with chronic hepatitis C virus (HCV) is evolving at a rapid p

259 e direct-acting antivirals (DAA) in treating chronic hepatitis C virus (HCV) is limited by low screen

260 The global burden of disease attributable to chronic hepatitis C virus (HCV) is very large, yet the u

261 1 healthy individuals (NC) (n = 20), group 2 chronic hepatitis C virus (HCV) patients (n = 20), group

262 Impaired T-cell responses in chronic hepatitis C virus (HCV) patients have been repor

263 The optimal retreatment strategy for chronic hepatitis C virus (HCV) patients who fail direct

264 In nontransplant patients with chronic hepatitis C virus (HCV), HCV genotype has been l

265 ntibodies (FPAs) have been well described in chronic hepatitis C virus (HCV), this has not been evalu

266 the risk of chronic kidney disease (CKD) in chronic hepatitis C virus (HCV)-infected patients and th

267 We prospectively evaluated 251 chronic hepatitis C virus (HCV)-infected subjects (31% h

268 hronic liver disease (CLD), and particularly chronic hepatitis C virus (HCV)-related hepatitis.

269 d with human immunodeficiency virus (HIV) or chronic hepatitis C virus (HCV).

270 predictive of treatment-induced clearance in chronic hepatitis C virus (HCV).

271 virin (RBV) in children and adolescents with chronic hepatitis C virus (HCV).

272 s still regarded as the standard of care for chronic hepatitis C virus (HCV).

273 ed risk of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV).

274 evir + TMC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus genotype (GT)1-infected treatm

275 ment for 6 weeks or less among patients with chronic hepatitis C virus genotype 1 infection.

276 afe and highly effective in adolescents with chronic hepatitis C virus genotype 2 or 3 infection.

277 ns with or without ribavirin as treatment of chronic hepatitis C virus in solid organ transplant reci

278 Chronic hepatitis C virus infection activates an intrahe

279 Sixty six patients with chronic hepatitis C virus infection and eligible for inc

280 Children with chronic hepatitis C virus infection have limited treatme

281 -acting antiviral drugs for the treatment of chronic hepatitis C virus infection have reduced mortali

282 pulations after DAA therapy in patients with chronic hepatitis C virus infection in the context of th

283 Chronic hepatitis C virus infection is associated with s

284 Chronic hepatitis C virus infection is well-recognized a

285 ffective and well tolerated in patients with chronic hepatitis C virus infection, including those wit

286 nse (SVR) to interferon-based treatments for chronic hepatitis C virus infection, whereas Asian race

287 direct-acting antiviral drugs used to treat chronic hepatitis C virus infection.

288 ion for therapeutic intervention in treating chronic hepatitis C virus infection.

289 ent has revolutionized care of patients with chronic hepatitis C virus infection.

290 Severe liver disease caused by chronic hepatitis C virus is the major indication for li

291 iling the response to interferon therapy (in chronic Hepatitis C virus patients) and Influenza A viru

292 le degree of liver fibrosis in patients with chronic hepatitis C virus prohibiting cadaveric renal tr

293 acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increa

294 recommendations on the care of patients with chronic hepatitis C virus who have achieved SVR.

295 lular carcinoma was overrepresented, whereas chronic hepatitis C was underrepresented, in reported Un

296 ting new direct-acting antivirals (DAAs) for chronic hepatitis C were the major focus of interest at

297 This represents a major difference from chronic hepatitis C, where numerous previous studies hav

298 s B vaccination among patients in China with chronic hepatitis C who are not in treatment.

299 To address this issue, 126 patients with chronic hepatitis C who completed pegylated IFN plus rib

300 for the treatment of adults with genotype 1 chronic hepatitis C who were prior relapsers.